Guidelines : Rheumatoid Arthritis (Moderate or Severe disease)
Detail
Condition :
Rheumatoid Arthritis (Moderate or Severe disease)
Keywords :
Abatacept, adalimumab, etanercept, anakinra, baricitinib, certolizumab, golimumab, infliximab, rituximab, tocilizumab, sarilumab, tofacitinib, upadacitinib, filgotinib, penicillamine, prednisone, sodium aurothiomalate, RA, Immunomodulator, Protein Kinase Inhibitor, JAK inhibitor, Janus Kinase, NICE TA, JAKI, anti-TNF, TNF alpha, b-cell, IL 6, interleukin inhibitor, biosimilar, biologic,
BNF Codes :
Committee Recommendations
Date
Committee Name
Narrative
Traffic Light Status
05 July 2023
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated Rheumatology Immunomodulator pathways (axial spondyloarthritis, psoriatic arthritis and rheumatoid arthritis (moderate and severe).
N/A
Documents
Type
Document
Review Date
Supplementary documents (CCG specific documents)
No records returned.
Drugs
Below are listed drugs that are used to treat Rheumatoid Arthritis (Moderate or Severe disease).
- Abatacept Red
- Adalimumab Red
- Anakinra Red
- Baricitinib Red
- Certolizumab Red
- Etanercept Red
- Filgotinib Red
- Golimumab Red
- Infliximab Red
- Penicillamine Red
- Prednisone Black
- Rituximab Red
- Sarilumab Red
- Sodium Aurothiomalate Red
- Tocilizumab Red
- Tofacitinib Red
- Upadacitinib Red